Download Files:

Probenecid

$55$106

Products Details

Product Description

– Probenecid is a potent and selective agonist of transient receptor potential vanilloid 2 (TRPV2) channels. Probenecid also inhibits pannexin 1 channels.

Web ID

– HY-B0545

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Metabolism-protein/nucleotide metabolism

Molecular Formula

– C13H19NO4S

References

– [1]Bakos E, et al. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8.|[2]Koch SE, et al. Probenecid: novel use as a non-injurious positive inotrope acting via cardiac TRPV2 stimulation. J Mol Cell Cardiol. 2012 Jul;53(1):134-44.|[3]Greene TA, et al. Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin. PLoS One. 2011;6(5):e20123.|[4]Silverman W, et al. Probenecid, a gout remedy, inhibits pannexin 1 channels. Am J Physiol Cell Physiol. 2008 Sep;295(3):C761-7.

CAS Number

– 57-66-9

Molecular Weight

– 285.36

Compound Purity

– 99.95

SMILES

– O=C(O)C1=CC=C(S(=O)(N(CCC)CCC)=O)C=C1

Clinical Information

– Launched

Research Area

– Metabolic Disease; Cancer

Solubility

– 0.5 M NaOH : 100 mg/mL (ultrasonic;adjust pH to 12 with NaOH)|DMSO : ≥ 100 mg/mL

Target

– Bacterial;HIV;TRP Channel

Pathway

– Anti-infection;Membrane Transporter/Ion Channel;Neuronal Signaling

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.